Abstract
A whole new area of investigation has emerged recently with regards to the anti-diabetic drug metformin and breast cancer. Metformins anti-breast cancer actions, observed in population studies, in rodents and in cultured tumour cells, are especially encouraging because they attack not only the most common bulk of the tumour cells but also the more rare tumour-initiating stem cells. Here, we illustrate the multifaceted and redundant mechanisms through which metformin-reprogrammed energy metabolism at both the organismal and cellular levels constitutes a novel and valuable strategy to prevent and treat breast cancer disease.
Keywords: Insulin, Diabetes, Metformin, Breast cancer, AMPK, Stem cells, Carcinogenesis, Hyperinsulinaemia, Biguanide derivative, Inflammation, Oestrogen, Apoptosis, IGF, Tumouricidal effect, Neoplasias, Adenocarcinomas, Thiazolidinediones, Sulfonylureas, Glibenclamide, Chemotherapy, Gluconeogenesis, Insulinaemia, Aerobic glycolysis, Oxidative phosphorylation, Mitosis, Glucose tolerance, Aromatase expression, Tyrosine kinase inhibitors, Antibodies, Supplementation, Lapatinib, Trastuzumab, Anti-HER2 therapy, PARP inhibitors, EGFR, Anti-cancer drugs, Cytotoxics, Anthracycline doxorubicin
Current Molecular Medicine
Title: Metformin and Energy Metabolism in Breast Cancer: From Insulin Physiology to Tumour-initiating Stem Cells
Volume: 10 Issue: 7
Author(s): A. Vazquez-Martin, C. Oliveras-Ferraros, S. Cufi, B. Martin-Castillo and J. A. Menendez
Affiliation:
Keywords: Insulin, Diabetes, Metformin, Breast cancer, AMPK, Stem cells, Carcinogenesis, Hyperinsulinaemia, Biguanide derivative, Inflammation, Oestrogen, Apoptosis, IGF, Tumouricidal effect, Neoplasias, Adenocarcinomas, Thiazolidinediones, Sulfonylureas, Glibenclamide, Chemotherapy, Gluconeogenesis, Insulinaemia, Aerobic glycolysis, Oxidative phosphorylation, Mitosis, Glucose tolerance, Aromatase expression, Tyrosine kinase inhibitors, Antibodies, Supplementation, Lapatinib, Trastuzumab, Anti-HER2 therapy, PARP inhibitors, EGFR, Anti-cancer drugs, Cytotoxics, Anthracycline doxorubicin
Abstract: A whole new area of investigation has emerged recently with regards to the anti-diabetic drug metformin and breast cancer. Metformins anti-breast cancer actions, observed in population studies, in rodents and in cultured tumour cells, are especially encouraging because they attack not only the most common bulk of the tumour cells but also the more rare tumour-initiating stem cells. Here, we illustrate the multifaceted and redundant mechanisms through which metformin-reprogrammed energy metabolism at both the organismal and cellular levels constitutes a novel and valuable strategy to prevent and treat breast cancer disease.
Export Options
About this article
Cite this article as:
Vazquez-Martin A., Oliveras-Ferraros C., Cufi S., Martin-Castillo B. and A. Menendez J., Metformin and Energy Metabolism in Breast Cancer: From Insulin Physiology to Tumour-initiating Stem Cells, Current Molecular Medicine 2010; 10 (7) . https://dx.doi.org/10.2174/156652410792630625
DOI https://dx.doi.org/10.2174/156652410792630625 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cognitive Functions under Anti-HER2 Targeted Therapy in Cancer Patients: A Scoping Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Comparing High LET <sup>227</sup>Th- and Low LET <sup>177</sup>Lu-trastuzumab in Mice with HER-2 Positive SKBR-3 Xenografts
Current Radiopharmaceuticals Targeting Histone Onco- Modifications Using Plant-Derived Products
Current Drug Targets Current Overview of Inorganic Nanoparticles for the Treatment of Central Nervous System (CNS) Diseases
Current Nanomaterials Use of Intravenous Immunoglobulin in the Treatment of Immune-Mediated Demyelinating Diseases of the Nervous System
Current Pharmaceutical Design Editorial: (Thematic Issue: Plant Polyphenols and Health Benefits)
Current Pharmaceutical Design The Therapeutic Role of Taurine in Ischaemia-Reperfusion Injury
Current Pharmaceutical Design Cancer Antibody Enhanced Real Time Imaging Cell Probes – a Novel Theranostic Tool using Polymer Linked Carbon Nanotubes and Quantum Dots
Anti-Cancer Agents in Medicinal Chemistry ERRATUM
Current Drug Targets DephosSitePred: A High Accuracy Predictor for Protein Dephosphorylation Sites
Combinatorial Chemistry & High Throughput Screening Targeting the Cancer-Stroma Interaction: A Potential Approach for Pancreatic Cancer Treatment
Current Pharmaceutical Design Membrane Disrupting Lytic Peptides for Cancer Treatments
Current Pharmaceutical Design The Functional Role of Long Non-coding RNA UCA1 in Human Multiple Cancers: a Review Study
Current Molecular Medicine TRAIL Agonists on Clinical Trials for Cancer Therapy: The Promises and the Challenges
Reviews on Recent Clinical Trials The Pim Kinases: New Targets for Drug Development
Current Drug Targets mTOR Targeted Cancer Chemoprevention by Flavonoids
Current Medicinal Chemistry Garcinia Benzophenones Inhibit the Growth of Human Colon Cancer Cells and Synergize with Sulindac Sulfide and Turmeric
Anti-Cancer Agents in Medicinal Chemistry Pro-inflammatory Cytokines in Animal and Human Gestation
Current Pharmaceutical Design Glycoprotein Targeting and Other Applications of Lectins in Biotechnology
Current Protein & Peptide Science Bortezomib in the Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery